ArticleFrontiers in oncology2025
Long-term trends and projections of ovarian cancer burden in China (1990 to 2040): an age-period-cohort analysis based on GBD 2021 data.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Effect of 6-gingerol on proliferation and apoptosis of ovarian cancer cells by the PI3K/AKT/mTOR pathway.Biochemistry and biophysics reports · 2026Article
- Analysis of ovarian cancer burden among reproductive-aged women and its association with the socio-demographic index from 1990 to 2021.World journal of surgical oncology · 2026Article
- Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older.JAMA network open · 2026Article
- Diagnostic performance and interobserver agreement of O-RADS US v2022 and its combination with serum biomarkers in surgically treated epithelial ovarian-adnexal masses.Frontiers in medicine · 2026Article
- Article
- Global Burden of Ovarian Cancer and Causal Risk Factors from 1990 to 2021: An Integrated GBD and Mendelian Randomization Analysis.International journal of women's health · 2026Article
- Patient Selection Metrics and Efficacy of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Analysis.International journal of women's health · 2026Article
- Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.PloS one · 2026Article
- Burden and Risk Factor Patterns of Reproductive System Tumors and Non-Tumor Diseases Among Asian Women, 1990-2021: Evidence from the GBD Study.International journal of women's health · 2026Article
- Temporal trends in cancer mortality attributable to high BMI in Asia: an age-period-cohort analysis based on GBD 1992-2021.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing burden of ovarian cancer is attracting widespread attention; the impact factors and the evolution trend of ovarian cancer burden need to be further studied. Methods: Ovarian cancer disease burden data for Chinese women were obtained from the Global Burden of Disease study 2021. We performed Age-Period-Cohort (APC) analysis to evaluate evolution trends across age, period, and cohort dimensions and identify contributing factors. Using the Bayesian Age-Period-Cohort (BAPC) model, we projected incidence and mortality trends through 2040. Results: In 2021, China recorded approximately 41,240 new ovarian cancer cases and 25,140 related deaths. From 1990 to 2021, age-standardized rates (ASRs) for incidence, mortality, and disability-adjusted life years fluctuated but increased steadily after 2015, with annual percentage changes of 1.6% (95%CI: 1.4%, 1.8%), 1.6% (95%CI: 1.4%, 1.9%), and 1.5% (95%CI: 1.3%, 1.6%), respectively. The APC model revealed a significant age effect with peak incidence occurring at 65-69 years; a period effect showing incidence and mortality rates resurged after 2015; and the cohort effects demonstrating bimodal incidence peaks in the birth cohorts of 1910-1914 and 1935-1939. Specifically, a 1% increase in the obesity rate was associated with a 3.06 (95%CI: 0.84, 5.28; Conclusions: The burden of ovarian cancer in China remains significant; the increasing obesity rate in women may be a driver. The ovarian cancer burden has resurged in China since 2015, and it is projected to continue increasing by 2040.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.